- Home
- MPB vs OPT Comparison
MPB vs OPT Comparison
Compare MPB & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- OPT
- Stock Information
- Founded
- MPB 1868
- OPT 1984
- Country
- MPB United States
- OPT Australia
- Employees
- MPB N/A
- OPT N/A
- Industry
- MPB Major Banks
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPB Finance
- OPT Health Care
- Exchange
- MPB Nasdaq
- OPT Nasdaq
- Market Cap
- MPB 525.0M
- OPT 574.0M
- IPO Year
- MPB N/A
- OPT 2020
- Fundamental
- Price
- MPB $29.78
- OPT $4.41
- Analyst Decision
- MPB Buy
- OPT Strong Buy
- Analyst Count
- MPB 2
- OPT 1
- Target Price
- MPB $36.00
- OPT $12.00
- AVG Volume (30 Days)
- MPB 67.9K
- OPT 19.4K
- Earning Date
- MPB 01-28-2025
- OPT 02-26-2025
- Dividend Yield
- MPB 2.68%
- OPT N/A
- EPS Growth
- MPB 14.41
- OPT N/A
- EPS
- MPB 2.91
- OPT N/A
- Revenue
- MPB $173,416,000.00
- OPT $261,859.00
- Revenue This Year
- MPB N/A
- OPT N/A
- Revenue Next Year
- MPB $19.26
- OPT $46,864.26
- P/E Ratio
- MPB $10.26
- OPT N/A
- Revenue Growth
- MPB 4.93
- OPT N/A
- 52 Week Low
- MPB $19.20
- OPT $1.79
- 52 Week High
- MPB $33.87
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- MPB 55.01
- OPT 66.30
- Support Level
- MPB $28.48
- OPT $3.59
- Resistance Level
- MPB $29.25
- OPT $3.90
- Average True Range (ATR)
- MPB 0.70
- OPT 0.26
- MACD
- MPB 0.23
- OPT 0.06
- Stochastic Oscillator
- MPB 93.36
- OPT 100.00
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.